Skip to main content
. 2022 Jan 8;23(2):679. doi: 10.3390/ijms23020679

Table 1.

Antibody Tumor-to-Plasma Ratio by Tumor Model.

Antibody Tumor Model Tumor/Plasma Ratio Cetuximab/8C2
8C2 LS174T 0.26 1.58
Cetuximab LS174T 0.41 -
8C2 LS174T/Sorafenib 0.20 1.35
Cetuximab LS174T/Sorafenib 0.27 -
8C2 NCI-N87 0.19 2.53
Cetuximab NCI-N87 0.48 -
8C2 Panc-1 0.08 1.50
Cetuximab Panc-1 0.12 -